{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-078152","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.115349+00:00","generated_at":"2026-06-01T01:05:47.179713+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications","bullets":["First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.","FDA cleared IND for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis (Ntrust-2).","Both trials are dose-escalation, open-label, multi-center, designed for up to 12 patients each.","Clinical data from Ntrust-1 and Ntrust-2 expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-078152","json":"https://secwatch.observer/filing/0000950170-24-078152.json","markdown":"https://secwatch.observer/filing/0000950170-24-078152.md","text":"https://secwatch.observer/filing/0000950170-24-078152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/0000950170-24-078152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/nktx-20240627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:05:47.179713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}